Infections

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Warts

Communicable Diseases

Papillomavirus Infections

Virus Diseases

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

Treated wart with CellFX device intervention

Control wart for each enrolled subject without intervention

The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.

CellFX Device

Richard Nuccitelli, PhD

This prospective, non-randomized, multicenter pivotal study is designed to evaluate the safety and effectiveness of the CellFX System in patients with cutaneous non-genital warts on all areas of the body, excluding the face.

The study will enroll healthy adult subjects with a minimum of two cutaneous non-genital warts, excluding the face, with each wart lesion not exceeding 10 x 10mm. One of the warts for each subject will be untreated and will serve as the subject's internal control. Macrophotography of all study warts will be captured along with Investigator assessments using the Wart Measurement Scale (WMS) and lesion measurements for wart reduction. All subjects will be followed at 7, 30, 60, 90 and 120-days post-initial CellFX treatment. All wart lesions are eligible for re-treatment up to 3 times over the course of the study. Adverse events will be documented.

CellFX System for the Treatment of Cutaneous Non-Genital Warts

A Prospective, Non-Randomized, Multicenter Pivotal Study of Nano-Pulse Stimulation™ (NPS™) Treatment of Cutaneous Non-Genital Warts

Percentage of Verrucae with Clearance (91-100% reduction)

Satisfaction with reduction in verrucae size or clearance of verrucae measured using the following scale; 5 (Satisfied), 4 (Mostly Satisfied), 3 (Partially Satisfied), 2 (Dissatisfied), 1 (Highly Dissatisfied)

Pulse Biosciences, Inc.

CellFX device using pre-defined energy protocols

CellFX Device: The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.

CellFX Treated Wart Lesion

CellFX Treated Verrucae

Age, Continuous

Sex: Female, Male

Race (NIH/OMB)

United States

Region of Enrollment

Class I

Class II

Class III

Class IV

The Fitzpatrick skin phototypes (FSP) were developed in Boston in 1975 for use with phototherapy. The scale's original purpose was to help determine a patient's risk of burning or tanning when exposed to UV light. The current scale classifies skin from types I to VI. Type I refers to skin that always burns, while type VI refers to skin that never burns. In general, a lower FSP means a person's skin burns more easily than it tans. A higher FSP means that a person's skin does not burn easily.

Fitzpatrick Skin Type

Treated

Control

Not treated

Verrucae Disposition

Common

Plantar

Flat

Wart Subtype

Hand

Foot

Knee

Ankle

Elbow

Wrist

Torso

Anatomic Location

Cryotherapy

Over the Counter Medical Treatment

Laser Treatment

Over the Counter and Laser Treatment

Electrocautery

Cantharone and Cryotherapy

Investigational Product

Aldara and Cryotherapy

Laser Treatment and Cryotherapy

Yeast Injection

History of Prior Verrucae Treatment

Subjects diagnosed with cutaneous warts, including common, flat and plantar subgroups

William A. Knape

Warts Treated With CellFX (Common, Flat, and Plantar)

Percent of verrucae clearance observed at 60-days post-last treatment. Reduction in verrucae size and/or clearance not assessed in the "Non-treated Control" Arm/Group or similar.

Percentage of Verrucae Cleared

All Treated Verrucae observed at 60-days post-last CellFX treatment

Subject Satisfaction

CellFX Treated Warts

Non-treated wart arm, one study wart per enrolled subject.

Non-Treated Controls

Overall Study

Neoplasms

Carcinoma

Carcinoma, Basal Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Basal Cell

CellFX System

Richard A. Nuccitelli, PhD

This prospective, multicenter, study is designed to evaluate the safety and effectiveness of the CellFX System in adults subjects with low-risk basal cell carcinoma (superficial and nodular) for complete histological clearance of the target lesion followed by surgical tumor excision 60 days post-treatment.

The study will enroll healthy adult subjects with confirmed low-risk (superficial and nodular) BCC lesion(s) by biopsy, excluding BCCs located on the face, neck, scalp, axilla, hands, feet, and genitals not exceeding 1.5 cm. Macrophotography of all study BCCs will be captured and clinically assessed by the site investigator for characterization of healing and scar appearance prior to and post-surgical excision. All subjects will be followed at 3, 7, 14, 30 and 60-days post-CellFX procedure and at 14, 30 and 60-days post-excision. Adverse events will be documented.

CellFX Treat & Resect Low-Risk BCC Feasibility Study

A Multicenter, Prospective, Treat and Resect Feasibility Study of the CellFX System for the Treatment of Low-Risk Basal Cell Carcinoma (BCC) Lesions

The primary effectiveness endpoint is the total number of lesions with complete histological clearance of the BCC lesion during histological review of microscopic analysis using H \& E slides. Counts and proportions will be assessed.

No serious adverse events related to CellFX Treatment or Procedure

Treatment of the BCC with CellFX System

CellFX System: Nano-Pulse Stimulation (NPS)

CellFX Procedure

Ethnicity (NIH/OMB)

Histological presence of superficial or nodular BCC

The total number of enrolled subjects in this study was 30 participants with 37 lesions.

William Knape / VP, Clinical, Regulatory and Quality Affairs

Number of Lesions With BCC Histological Clearance

Number of Participants With Treatment Related Serious Adverse Events

Head and Neck Neoplasms

Neoplastic Cells, Circulating

Neoplasm Metastasis

Neoplastic Processes

All Drugs and Chemicals

Immunomodulating Agents

MADMAS will include 30 patients with metastatic NSCLC and 30 patients with metastatic head and neck cancers; patients will NSCLC will receive an immunotherapy-based treatment in first line metastatic setting; patients with head and neck cancers are included if they are planned to receive an immunotherapy-based treatment, whatever the line.

Blood draws will be realized at the following time points:

C1T1: at the baseline, before treatment administration. C1T2: cycle 1, after treatment administration. C2T1: the day of the 2nd cycle, before treatment administration. C2T2: the day of 2nd cycle, after treatment administration. C3T1: the day of the 3rd cycle, before treatment administration. C3T2: the day of 3rd cycle, after treatment administration.

Blood draws

Pierre PHILOUZE, MD

Sara CALATTINI

Sébastien COURAUD, MD

Immunotherapy is widely administrated as anticancer treatment in metastatic setting. Despite a proved efficacy in several cancer types and clinical situations, it exists a wide variability of responses in terms of efficacy and toxicity. The rate of responders depends mostly on the type of pathology, with 40% of responders among melanoma patients, 20-30% among lung and head and neck cancer patients and only 1% of responders among pancreatic cancer patients. Thus, the main challenge today is to be able to select patients for whom the treatment is likely to be effective. Several studies suggested that tumors with a high mutational burden and expressing PD-L1 are better responders to immunotherapy.

However, a proportion of PD-L1 negative cancers responds to immunotherapy, suggesting that other parameters have to be considered together with PD-L1 expression. Of that, the immunotherapy clearance seems to have an impact on overall survival, but larger studies, including different molecules and cancer types, are needed to better understand the correlation between the clearance and the response to immunotherapy.

Tumor cells released from the primary tumor in the blood circulation (CTCs, for circulating tumor cells) are considered as "liquid biopsies", as they contain the entire genetic and phenotypic information representative of the tumor, including PD-L1 expression. Thus, the variation of PD-L1 expression under treatment can be easily followed-up on blood samples collected during the time.

The objective of MADMAS is to study the correlation between the immunotherapy clearance, measured at the different times during treatment, and the variation of the number of CTCs expressing PD-L1 after two cures of treatment.

MADMAS will enroll patients with lung or head and neck cancers, treated with an immunotherapy-based therapy. Blood samples will be collected at the baseline and before the first two cures of treatment. The immunotherapy clearance will be measured with an innovative approach of Mass Spectrometry, and PD-L1 expression will be measured on CTCs, purified with a highly sensitive microfluidics technology.

Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers

Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Patients With Lung and Head and Neck Cancers, Treated With an Immunotherapy-based Therapy

The clearance and the number of PD-L1 positive cells will be measured on blood samples collected the day of the third immunotherapy administration (each cycle is 14 to 28 days, depending on the type of immunotherapy).

time elapsed between the first immunotherapy administration and the death

time elapsed between the first immunotherapy administration and progression

The level of PD-L1 expression will be measured by ICH on tissue from primary tumor surgery/biopsy through study completion, an average of 2 years.

Baseline transcriptomic profile of CTCs isolated form peripheral blood: the transcriptomic profile of CTCs will be analyzed by NGS (Next-Generation Sequencing) from blood samples collected at cycle 1 day 1, before treatment administration.

The transcriptomic profile of CTCs will be analyzed by NGS (Next-Generation Sequencing) from blood samples collected after the 1st cycle of treatment (cycle length between 14 and 21 days depending on the type of immunotherapy)

The transcriptomic profile of CTCs will be analyzed by NGS (Next-Generation Sequencing) from blood samples collected at the end of cycle 2 (each cycle is 21 days).

the CTCs transcriptomic profile (measure 4) will be obtained with the NGS method; the analyses of these profiles will imply statistical models of logistic regression (Lasso Method). These data will be compared with clinical data on efficacy (PFS measured at 2 years after the beginning of treatment) and toxicity (stopping treatment for toxicity before the third cycle).

Hospices Civils de Lyon

CellFX device using pre-defined energy protocols

Cryosurgery will be standardized across all investigational sites. Investigators will perform the Cryosurgical procedure using the Brymill Cry-Ac B700 Liquid Nitrogen Sprayer.

CellFX System Device

Cryosurgery will be standardized across all investigational sites using the Brymill Cry-Ac spray canister with standard cryoprobe.

Cryosurgery Liquid Nitrogen Sprayer

This prospective, multicenter, single-blinded, randomized comparison study is designed to compare the safety and effectiveness of the CellFX System to Cryosurgery for the clearance of cutaneous non-genital common warts on all areas of the body excluding the scalp, nose, within the orbital region of the face, plantar or periungual area in healthy adult subjects.

The study will enroll healthy adult subjects with a minimum of two cutaneous non-genital warts, excluding the face, with each wart lesion not exceeding 10 x 10mm. Macrophotography of all study warts will be captured along with a blinded site Investigator to characterize wart healing, wart clearance and wart reduction. All subjects will be followed at 7, 30, 60, and 90-days following the last CellFX or Cryosurgical Procedure. All wart lesions are eligible for up to a total of 3 treatments over the course of the study. Adverse events will be documented.

Each subject will be evaluated by the blinded site investigator conducting assessment of outcomes at 7, 30, 60, and 90-days following CellFX and Cryosurgical treatments.

CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts

A Multicenter, Prospective, Randomized, Comparison IDE Study Between the Pulse Biosciences CellFX System and Cryosurgery for the Treatment of Cutaneous Non-Genital Common Warts

The primary effectiveness endpoint is the percentage of warts resolved or cleared as assessed "live" by the blinded site investigator at 30 days after the last treatment with CellFX or Cryosurgical Procedure.

The safety endpoint is the percentage of warts with skin textural changes where the wart was originally treated and showed textual changes of the surrounding skin where the wart was treated and included; scabbing, swelling, crusting, blister, or ulceration when assessed by the blinded site investigator.

The skin change safety event is defined as the presence of hyperpigmentation, hypopigmentation, or scarring as assessed by the blinded site investigator.

CellFX device using pre-defined energy protocols

CellFX System Device: The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.

Cryosurgery will be standardized across all investigational sites. Investigators will perform the Cryosurgical procedure using the Brymill Cry-Ac B700 Liquid Nitrogen Sprayer.

Cryosurgery Liquid Nitrogen Sprayer: Cryosurgery will be standardized across all investigational sites using the Brymill Cry-Ac spray canister with standard cryoprobe.

Cryosurgical Procedure

Total

Total number of enrolled warts per treatment

William A. Knape, VP Clinical, Regulatory, and Quality Affairs

The population consisted of participants with treated warts and evaluated at 30-days following the last CellFX or Cryosurgical Procedure up to a maximum of 3 months.

Percentage of Warts Resolved

The population consisted of participants with treated warts and evaluated for skin textural changes at 30-days following the last CellFX or Cryosurgical Procedure up to a maximum of 3 months.

Percentage of Warts Treated With Skin Textural Changes

The population consisted of participants with treated warts and evaluated at 90-days following the last CellFX or Cryosurgical Procedure up to a maximum of 6 months.

Presence of Pigmentary and Scarring Skin Changes

Rare Diseases

Squamous Intraepithelial Lesions of the Cervix

Uterine Cervical Dysplasia

Precancerous Conditions

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Cervical Intraepithelial Neoplasia

Double-freezing cryotherapy was done within one month after the primary hpv testing was positive. Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.

Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.

Bandit Chumworathayi, MD

Persistent human papillomavirus (HPV) infections is the single necessary cause of cervical cancer. Cervical cancer is still the major health problem in the developing countries. It has been the first rank women's cancer in Thailand for many decades. Approximately 10-20% of Thai women have the high-risk HPV (HR-HPV) infections in their cervices. This will frequently lead to low-grade squamous intraepithelial lesions (LSILs) (10%), high-grade squamous intraepithelial lesions (HSILs) (0.8%), and finally, cervical cancers (0.16%) within 10-20 years. The treatment options for LSILs are either observation or ablative surgery. However, in our institute, cryotherapy, which is the one of ablative surgery, is more frequently used to comfort our women. It is not only effective but safe with only minimal side effects; watery leukorrhea for 2-4 weeks, and local cervical infection not more than 1%. Contraindication to this procedure are active cervical infection, lesion of 2 mm-larger than probe, lesion inside cervical os and suspected cervical cancer. Additionally, in developing countries such as Thailand, this treatment is safe, acceptable, feasible and effective. Patients with LSILs could also have this treatment in some rural area from the 10-days trained nurses. Fortunately, recent reports showed that cryotherapy has abilities not only in clearing LSILs but also clearing the HPV infections, its necessary cause. However, there are no randomized controlled trial compared its clearing ability between observation and cryotherapy. Therefore, a randomized controlled trial is needed to demonstrate that. Findings from this trial will contribute enormously to older women who already get infected by HPV. Aside from preventing cervical cancer in treated woman, cryotherapy could also give her relief from worrying about having a time-bomb like HPV infection in her cervix.

This will be a hospital-based, parallel, assessor-blinded, randomized controlled trial. Study subjects refer to LSIL patients, more than 30 years-old, with positive HPV testing who do not have any contraindication of performing cryotherapy. Therefore, after recruitment LSIL patients whose age more than 30 years-old, we will exclude only those who have negative HPV testing or any contraindications of performing cryotherapy. The primary outcome is HPV clearance (negative HPV testing for the baseline HPV type) at 12 months after the treatment. Subjects will be randomly allocated to be treated by cryotherapy or observation only by using block randomization with varied block size of 2, 4, and 6. The sample size of at least 25 for each arm was planned to have the power of 80% to detect 20% difference rates of HPV clearance after 12 months of treatment between the two arms, with significance level of 0.05, two-sided test.

Study population:

Biopsy-confirmed LSIL patients, age more than 30 years-old, referred to either Srinagarind Hospital's, Khon Kaen Hospital's, or Roi Et Hospital's colposcopic clinics.

Inclusion criteria:

* Baseline HPV testing is positive.
* Be able to give their informed consent to this study.

Exclusion criteria:

* Having active cervical infection
* Having lesion of 2 mm-larger than probe
* Having lesion inside cervical os
* Having suspected cervical cancer lesion

Sample and sample size:

From previous studies, HPV clearance rate after cryotherapy at 12 months is 83.9%. (Elfgren, 2002) Spontaneous HPV clearance rate in young women at 24 months is 70%. (Moscicki, 1998) However, this HPV clearance rate in women older than 34 years-old at 12 months is only 53.6%. (Clavel, 2005) Using these numbers respectively as PE and PC putting in the formula below, we can calculate our sample size in each group. The sample size will be calculated to detect the 20-40% difference between the HPV clearance rates after 12 months, at significant level of 95% and power of 80% (two-sided test), using the approach of Lachin that was reviewed in the paper of Donner.(Donner, 1984)

Required sample size at different rate of clearance

P-control P-experimental Alpha level Power N Difference 95%CI 0.50 0.70 5% 80% 103 20 6.9-33.1 0.50 0.75 5% 80% 66 25 9-41 0.50 0.80 5% 80% 45 30 11.3-48.7 0.50 0.85 5% 80% 33 35 14-56 0.50 0.90 5% 80% 25 40 17.1-62.9

The sample size of at least 25 patients in each group will be chosen because of its precision and feasibility. Such sample size can detect 40% difference of HPV clearance rate between the two groups, at 95% significant level, with the power of 80%, 95%CI of 17.1-62.9, respectively.

Instruments:

After signing on the consent form, all eligible patients will be examined by the baseline standard procedures and PCR-HPV testing for 37 HPV types. Only positive HPV testing ones will be enrolled in the trial and then randomized to receive the cryotherapy or observation. The method of block randomization, with block size varies from 2 to 6, will be used to allocate treatments.

The allocation ratio is 1:1. The allocation sequence will be generated by computer, using STATA software version 10.0.

Based on the obtained schedule, the number of sealed envelopes, which are equal to the required blocks, will be prepared and labeled. Each envelope contains the corresponding sealed allocation cards that will allocate treatments to patients.

Colposcopy and cryotherapy instruments are available in our colposcopic clinic. However, we will reimburse for all CO2-gases tanks and materials used for Pap smears and HPV testing.

The people, who prepare the randomized scheme, will not involve in the trial. The allocation schedule will be concealed to the assessor (who measure the HPV testing) until the end of trial.

Data collection and measurement:

Because of the difference between two treatments, only the assessor (who measure the HPV testing) will be blinded from the treatments.

The specimens will be sent to the assessor without patient's name or HN that can be linked to the treatment received. They will be provided only the study ID number in which only the principle investigator can link it to the treatment received.

The main outcome is HPV clearance. It is measured by the gold-standard HPV testing. This will be performed at baseline and 12 months later.

Data analysis:

There were two main parts of analysis - describing selected characteristics of the study patients and analysis for answering the research questions. The first part, selected baseline characteristics of the patients in each treatment were compared i.e. age, sex, sexual experiences, underlying diseases, etc. Comparability of the distribution of those selected characteristics based on judgment rather than statistical significant tests. In this part, proportion was use for summarizing categorical data. For continuous data, the statistics include mean, standard deviation, minimum, maximum, and median.

For the second part, the analysis was based on the group in which the study patients were randomized (intention-to-treat basis). The different rate of clearance between the two arms of the trial and its 95% confidence interval will be calculated. This will be done at 12 months after the treatment. Z-test will be used for testing if such differences are different from zero. Multiple logistic regression will be used to control effects of any important confounding factors. Absolute risk reduction (ARR), relative risk reduction (RRR) and number needed to treat (NNT) will also be calculated.

The statistical analysis of this clinical trial will be performed based on intention-to-treat principle. All hypothesis tests are two-tailed at significant level of 0.05. Statistical package for all analysis is STATA version 10.0.

Cryotherapy for Human Papillomavirus Clearance in Biopsy-confirmed Cervical Low-grade Squamous Intraepithelial Lesions

Cryotherapy for Human Papillomavirus Clearance in Biopsy-confirmed Cervical Low-grade Squamous Intraepithelial Lesions: a Randomized Controlled Trial

At 12 months after treatment, a patient with negative results for HPV testing of previous types was considered as a clearance.

Khon Kaen University

Clinical Epidemiology Unit (CEU)

Observation

Age, Categorical

Age Continuous

Thailand

Bandit Chumworathayi

Number of Patients With Human Papillomavirus Clearance

Nutritional and Metabolic Diseases

Blood and Lymph Conditions

Obesity

Hematologic Neoplasms

Body Weight

Hematologic Diseases

Anti-Infective Agents

Acyclovir

Aaron Cumpston, PharmD

Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking acyclovir to determine if higher body weights affect drug exposure. The information gathered from this study will help understand if patients with higher body weights need a different dosing plan.

Patients receiving acyclovir as standard of care will be enrolled into this study. They will have blood draws once before they take acyclovir and 10 times after they take the acyclovir (over a total of 12 hours). These patients will be in the hospital already and will not need to make additional trips back to have blood drawn. A total of about 4-5 tablespoons of blood will be drawn for this study. 7 obese patients and 7 matched, non-obese patients will be enrolled into this study.

Effect of Body Mass on Acyclovir Pharmacokinetics

West Virginia University

Pharmacy Clinical Specialist - BMT/Hematologic Malignancy

Condylomata Acuminata

Sexually Transmitted Diseases

Sexually Transmitted Diseases, Viral

Antineoplastic Agents

Imiquimod

Immunologic Factors

Adjuvants, Immunologic

Interferons

It will be composed of 51 individuals between 18 and 50 years old with anogenital warts to which will be applied betaglucin gel at 0.2%.

51 individuals between the ages of 18 and 50 will receive 5% imiquimod.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CellFX System for the Treatment of Cutaneous Non-Genital Warts	NCT04554394	Warts Warts Hand Verruca	CellFX Device	21 Years - 80 Years	Pulse Biosciences, Inc.
CellFX Treat & Resect Low-Risk BCC Feasibility Study	NCT04918381	BCC - Basal Cel... BCC Excision Margin	CellFX System	22 Years - 85 Years	Pulse Biosciences, Inc.
Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers	NCT05091190	Metastatic NSCL... Metastatic Head...	Blood draws	18 Years -	Hospices Civils de Lyon
CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts	NCT04738734	Warts Warts Hand Verruca	CellFX System D... Cryosurgery Liq...	22 Years - 80 Years	Pulse Biosciences, Inc.
Cryotherapy for Human Papillomavirus Clearance in Biopsy-confirmed Cervical Low-grade Squamous Intraepithelial Lesions	NCT00566579	Human Papilloma...	Cryotherapy	30 Years -	Khon Kaen University
Effect of Body Mass on Acyclovir Pharmacokinetics	NCT01714180	Hematological M... Pharmacokinetic...		18 Years -	West Virginia University
Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers	NCT05091190	Metastatic NSCL... Metastatic Head...	Blood draws	18 Years -	Hospices Civils de Lyon
Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study	NCT03901690	Genital Wart Vi...	Betaglucin solu... Imiquimod 5% cr...	18 Years - 50 Years	Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri
CellFX Treat & Resect Low-Risk BCC Feasibility Study	NCT04918381	BCC - Basal Cel... BCC Excision Margin	CellFX System	22 Years - 85 Years	Pulse Biosciences, Inc.
CellFX System for the Treatment of Cutaneous Non-Genital Warts	NCT04554394	Warts Warts Hand Verruca	CellFX Device	21 Years - 80 Years	Pulse Biosciences, Inc.
CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts	NCT04738734	Warts Warts Hand Verruca	CellFX System D... Cryosurgery Liq...	22 Years - 80 Years	Pulse Biosciences, Inc.
Effect of Body Mass on Acyclovir Pharmacokinetics	NCT01714180	Hematological M... Pharmacokinetic...		18 Years -	West Virginia University
Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study	NCT03901690	Genital Wart Vi...	Betaglucin solu... Imiquimod 5% cr...	18 Years - 50 Years	Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri

Spots Global Cancer Trial Database for clearance

Every month we try and update this database with for clearance cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for clearance

Every month we try and update this database with for clearance cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for clearance cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.